Core Insights - Astellas Pharma Inc. will present new data on IZERVAY™ (avacincaptad pegol intravitreal solution) at the ARVO and RWC meetings, focusing on geographic atrophy (GA) and patient experiences [1][2][3] Group 1: Presentation Details - The data includes nine abstracts, with two oral presentations, analyzing biomarkers, patient experiences, and mechanisms of disease from the GATHER Phase 3 studies of IZERVAY for GA secondary to age-related macular degeneration (AMD) [2][3] - Key presentations at the 2025 ARVO Annual Meeting include topics on the association of baseline central subfield ellipsoid zone integrity with visual acuity and future vision loss, and understanding the experience of people living with GA in various countries [3][4][6] Group 2: Research Highlights - Research highlights include multiple posters evaluating imaging data from the GATHER1 and GATHER2 studies, linking structure and function in GA, and preclinical posters refining the mechanism of action of avacincaptad pegol [4][5] - Qualitative studies assess the impact of GA symptoms on health-related quality of life (HRQoL) and coping mechanisms used by patients in the U.S., Spain, Germany, and France [4][5] Group 3: Clinical Trials - The GATHER clinical trials demonstrated that IZERVAY met its primary endpoint, with GATHER1 enrolling 286 participants and GATHER2 enrolling 448 participants, evaluating the safety and efficacy of monthly 2 mg intravitreal administration [15][17] - In year 2 of the GATHER2 study, patients previously treated with IZERVAY were re-randomized to receive either monthly or every other month dosing, while those who received sham continued with sham treatment [18]
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses